Alarming trends in the rates of premature coronary heart disease among younger women in wealthy nations prompted a group of U.S. researchers to try to pinpoint their risk factors for CHD ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback